All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @misstealjedi1 on TikTok · 15s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @misstealjedi1's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Make me all I want for this night
  2. 0:05It is you
  3. 0:07Yeah, yeah, yeah
  4. 0:09Slits in the face, all I want for you
  5. 0:12Oh, yeah, yeah

@misstealjedi1's Zepbound progress claim, fact-checked

Miss Teal Jedi

TikTok creator

151.1K viewsWatch on TikTok

Quick answer

The video appears to be a personal weight loss progress post from a Zepbound (tirzepatide) user, with no explicit medical claims made in the transcript. The content is consistent with patient-reported outcomes on dual GIP/GLP-1 agonist therapy, where gradual body weight reduction over months is clinically expected based on SURMOUNT-1 trial data. No specific dosing, treatment protocols, or disease cure claims were identified in the available transcript.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @misstealjedi1's Zepbound progress claim, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@misstealjedi1's Zepbound progress claim, fact-checked" from Miss Teal Jedi. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video appears to be a personal weight loss progress post from a Zepbound (tirzepatide) user, with no explicit medical claims made in the transcript.

The reason this review is not generic is the source wording and the canonical claim label "glp1 it s progress glp1 zepboundcommunity glp1forweightloss." In this clip, the useful excerpt is: "Make me all I want for this night It is you Yeah, yeah, yeah Slits in the face, all I want for you Oh, yeah, yeah" That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 drug.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video appears to be a personal weight loss progress post from a Zepbound (tirzepatide) user, with no explicit medical claims made in the transcript.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video appears to be a personal weight loss progress post from a Zepbound (tirzepatide) user, with no explicit medical claims made in the transcript. The content is consistent with patient-reported outcomes on dual GIP/GLP-1 agonist therapy, where gradual body weight reduction over months is clinically expected based on SURMOUNT-1 trial data. No specific dosing, treatment protocols, or disease cure claims were identified in the available transcript.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide 15mg produced an average 20.9% body weight reduction over 72 weeks in adults with obesity.
  • Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 drug. It is not clinically equivalent to semaglutide or liraglutide despite shared hashtags.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide 15mg produced an average 20.9% body weight reduction over 72 weeks in adults with obesity.
  • Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 drug. It is not clinically equivalent to semaglutide or liraglutide despite shared hashtags.
  • Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed roughly two-thirds of weight lost on semaglutide was regained within a year of stopping, suggesting these are long-term medications for most users.
  • Compounded tirzepatide is not the same as FDA-approved Zepbound. Formulation, quality control, and inactive ingredients differ and are not regulated equivalently.
  • Individual results vary significantly. SURMOUNT-1 participants ranged from minimal responders to those losing over 25% of body weight, so one person's progress post is not a benchmark.
  • GI side effects including nausea and vomiting are common during dose escalation and affect a substantial portion of users in clinical trials.
  • This specific video contains no spoken health claims and no prescriptive medical advice, which puts it in a lower-risk category compared to much GLP-1 content circulating on TikTok.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @misstealjedi1 actually say?

Honestly? Not much that can be fact-checked. The transcript captured here is song lyrics, not health claims. The words "slits in the face, all I want for you" appear to be audio from a trending sound, not original spoken content about GLP-1 medications or weight loss.

What we do have is context: the caption reads "It's progress" with a heart emoji, paired with hashtags including #glp1, #zepboundcommunity, and #glp1forweightloss. The video likely shows a visual progress update, a before-and-after style clip, or a body transformation moment set to music. That format is extremely common in the Zepbound community on TikTok, where users document their weight loss journeys without making explicit medical claims.

So there are no direct spoken health claims to fact-check here. What we can do is look at what this type of content implies and whether those implications hold up.

Does the science back this up?

If the implicit claim is that tirzepatide (Zepbound) produces meaningful, visible weight loss progress, yes, the evidence is strong. This is one of the better-supported outcomes in recent obesity medicine research.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) followed 2,539 adults with obesity over 72 weeks. Participants on the highest dose of tirzepatide (15 mg) lost an average of 20.9% of their body weight. That is not a rounding error. For context, earlier GLP-1 agents like liraglutide produced roughly 5-8% weight loss in comparable trials.

Progress posts like this one, showing incremental change over weeks or months, align with how tirzepatide actually works. It is not a fast drug. Most users see gradual loss over a year or more, with results varying significantly by dose, diet, and individual metabolism. The "progress" framing is clinically reasonable.

What did they get wrong (or right)?

There are no explicit claims to flag as wrong here, which is actually worth noting. A lot of GLP-1 content on TikTok overclaims: people say things like "this cured my food noise" or "I stopped taking insulin" without context. This post does not appear to do that.

What the content does right is keep it personal. "It's progress" is not a medical claim. It is a personal update. That kind of framing avoids the trap many creators fall into, positioning their individual experience as universal or prescriptive.

The one mild concern is the hashtag #glp1forweightloss, which lumps multiple drugs together. GLP-1 receptor agonists vary significantly in their mechanisms and outcomes. Tirzepatide is a dual GIP/GLP-1 agonist, not a pure GLP-1 drug. Semaglutide, liraglutide, and tirzepatide are not interchangeable, and content that implies they are does a disservice to people trying to understand their options.

What should you actually know?

Progress on GLP-1 or dual-agonist medications is real, documented, and for many people, significant. But a few things often get lost in the scroll.

  • Weight loss results vary widely. SURMOUNT-1 showed a range from minimal loss to over 25% body weight reduction. The average is not everyone's experience.
  • These medications require ongoing use. Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed that stopping semaglutide led to regain of roughly two-thirds of lost weight within a year.
  • Side effects are common, especially early on. Nausea, vomiting, and GI discomfort affect a significant portion of users, particularly during dose escalation.
  • Compounded versions of these drugs are not equivalent to brand-name Zepbound or Wegovy. Formulation, inactive ingredients, and quality controls differ. Do not assume a compounded tirzepatide produces the same result as the FDA-approved product.
  • Progress posts are motivating but not medical advice. What worked for one person on one dose at one point in their journey is not a template.

If you are considering a GLP-1 or dual-agonist medication, talk to a licensed provider who can review your full health history, not just your TikTok feed.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Miss Teal Jedi · TikTok creator

151.1K views on this video

It’s progress ❤️ #glp1 #zepboundcommunity #glp1forweightloss

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) found tirzepatide 15mg produced?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide 15mg produced an average 20.9% body weight reduction over 72 weeks in adults with obesity.

What does the video say about tirzepatide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 drug. It is not clinically equivalent to semaglutide or liraglutide despite shared hashtags.

What does the video say about wilding et al. (2022, diabetes, obesity?

Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed roughly two-thirds of weight lost on semaglutide was regained within a year of stopping, suggesting these are long-term medications for most users.

What does the video say about compounded tirzepatide?

Compounded tirzepatide is not the same as FDA-approved Zepbound. Formulation, quality control, and inactive ingredients differ and are not regulated equivalently.

What does the video say about individual results vary significantly. surmount-1 participants ranged from minimal responders?

Individual results vary significantly. SURMOUNT-1 participants ranged from minimal responders to those losing over 25% of body weight, so one person's progress post is not a benchmark.

What does the video say about gi side effects including nausea?

GI side effects including nausea and vomiting are common during dose escalation and affect a substantial portion of users in clinical trials.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Miss Teal Jedi, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.